ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2891 • 2013 ACR/ARHP Annual Meeting

    Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3

    Carla M. Cuda1, Alexander V. Misharin2, Rana Saber2 and Harris R. Perlman3, 1Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Medicine/Rheumatology, Northwestern University, Chicago, IL, 3Feinberg School of Medicine, Northwestern University, Chicago, IL

    Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE).  While DCs from SLE patients exhibit elevated activation,…
  • Abstract Number: 2892 • 2013 ACR/ARHP Annual Meeting

    Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis

    Takeshi Machida1, Natsumi Sakamoto1, Teizo Fujita1, Minoru Takahashi2 and Hideharu Sekine1, 1Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and…
  • Abstract Number: 2893 • 2013 ACR/ARHP Annual Meeting

    Intestinal Microbiota Plays a Critical Role In The Production Of Antinuclear Antibodies In Lymphopenia-Induced Autoimmunity

    Toshiki Eri1, Kimito Kawahata1, Mitsuru Imamura1, Takeyuki Kanzaki2, Lisa Akahira1, Kazuya Michishita1, Makoto Dohi1, Takeshi Tokuhisa3 and Kazuhiko Yamamoto4, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, 3Development Genetics, Graduate School of Medicine, Chiba University, Chiba city, Chiba, Japan, 4Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Production of antinuclear autoantibodies (ANAs) is one of the major characteristics of the systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), but the…
  • Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting

    Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus

    Laurie Davis1, Yong Du2, Tianfu Wu3 and Chandra Mohan4, 1Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 2Internal Medicine - Rheumatic Diseases, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 3Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 4University of Houston, Houston, TX

    Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…
  • Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting

    Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N. Bruce1, Aidan O'Keefe2, Li Su3, Vernon Farewell4, John G. Hanly5, Susan Manzi6, Murray B. Urowitz7 and Systemic Lupus International Collaborating Clinics (SLICC)8, 1Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, 2MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, 3MRC Biostatistics Unit, Cambridge, United Kingdom, 4MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 5Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, 6Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada

    Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…
  • Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study

    J. Antonio Avina-Zubieta1, Eric C. Sayre2, Diane Lacaille1,3 and John M. Esdaile4, 1Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, 2Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Medicine, University of British Columbia, Vancouver, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

    Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…
  • Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases

    Niels Eijkelkamp1, Sarita Hartgring2, Cristine Steen-Louws3, Hanneke Willemen4, Qiu-Ling Mao-Ying5, Cobi Heijnen5, Erik Hack6, Annemiek Kavelaars5 and J.A.G. van Roon7, 1Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, 2Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3UMC Utrecht, Utrecht, Netherlands, 4NIDOD, UMC Utrecht, Utrecht, Netherlands, 5MD Anderson Cancer Center, Houston, TX, 6Immunology, UMC Utrecht, Utrecht, Netherlands, 7Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
  • Abstract Number: 2859 • 2013 ACR/ARHP Annual Meeting

    Pain Pathway Activation In Dorsal Root Ganglia and Dorsal Horn In a Murine Surgical Model Of Osteoarthritis

    Rachel E. Miller1, Phuong Tran2, Richard J. Miller3 and Anne-Marie Malfait4, 1Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, 4Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL

    Background/Purpose: Using a surgical mouse model of osteoarthritis (OA), destabilization of the medial meniscus (DMM), we monitor pain and associated pathways over a period of…
  • Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting

    Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis

    Patrícia Costa-Reis1, Pierre Russo2 and Kathleen E. Sullivan3, 1Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, 2Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…
  • Abstract Number: 2861 • 2013 ACR/ARHP Annual Meeting

    Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci

    Robert M. Clancy1, Jill P. Buyon2, Nathalie Costedoat-Chalumeau3, Antonio Brucato4, Kateri Levesque5, Véronique Ramoni6, Miranda C. Marion7, Mary Comeau8, Satria Sajuthi9, Paula S. Ramos10, Robert P. Kimberly11, Timothy D. Howard12 and Carl D. Langefeld13, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Internal Medicine, Hopital Cochin, Paris, France, 4Internal Medicine, USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy, 5Medicine Interne, Hopital Cochin, Paris, France, 6Rheumatology, Rheumatology University of Pavia, Pavia, Italy, 7Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 8Wake Forest University Health Sciences, Winston-Salem, NC, 9Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 10Department of Medicine, Medical University of South Carolina, Charleston, SC, 11Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 12Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, 13Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC

    Background/Purpose:  Anti-Ro associated congenital heart block (CHB) exhibits a 33% concordance rate in monozygotic twins, 17.5% recurrence of disease and a high sibling risk ratio…
  • Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting

    Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis

    Imelda Balboni1, David Haddon2, Vivian Diep2, Cindy Limb2 and Paul Utz2, 1Pediatrics, Stanford University School of Medicine, Palo Alto, CA, 2Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
  • Abstract Number: 2863 • 2013 ACR/ARHP Annual Meeting

    Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis

    Anjali Patwardhan1, Katherine Lintner2, Lisa G. Rider3, Frederick W. Miller3, Terrance O'Hanlon3, Yee Ling Wu4, Bi Zhou2, Huanyu Wang4, David Newsom5, Peter White5, Charles H. Spencer6 and C. Yung Yu2, 1Pediatric Rheumatology, University of Missouri Women's and Children's Hospital, Columbia, MO, 2Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 3Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 4The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 5Biomedical Genomics Core, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 6Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a systemic and inflammatory vasculopathy that affects mainly proximal muscles and skin in children.  It is a rare but severe…
  • Abstract Number: 2864 • 2013 ACR/ARHP Annual Meeting

    Whole Exome Sequencing In Pediatric Patients With Early Onset Rare Immunodysregulatory Diseases That Present With Fever and Systemic Inflammation

    Adriana Almeida de Jesus1, Julie Niemela2, Yin Liu3, Steven Boyden4, Ivona Aksentijevich5, Daniel L. Kastner6, Thomas A. Fleisher7, Raphaela Goldbach-Mansky3 and Zuoming Deng8, 1Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2Laboratory Medicine, NIH Clinical Center, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 4National Human Genome Research Institute, NIH, Bethesda, MD, 5Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 6Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, 7Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD, 8Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

    Background/Purpose: WES (Whole Exome Sequencing) has increasingly become the tool of choice in translational research, providing molecular diagnoses in Mendelian diseases and identifying important genes…
  • Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting

    Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course

    AnneMarie C. Brescia1, Megan M. Simonds2, Suzanne M. McCahan2, Paul T. Fawcett2 and Carlos D. Rose1, 1Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, 2Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE

    Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
  • Abstract Number: 2866 • 2013 ACR/ARHP Annual Meeting

    Determining The Absolute Change In The Clinical Disease Activity Index (CDAI) To Define a Minimally Important Difference

    Jeffrey R. Curtis1, Shuo Yang2, Lang Chen3, Janet E. Pope4, Edward C. Keystone5, Boulos Haraoui6, Gilles Boire7, J. Carter Thorne8, Diane Tin9, Carol A. Hitchon10, Clifton O. Bingham III11 and Vivian P. Bykerk12, 1University of Alabama at Birmingham, Birmingham, AL, 2Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4St Joseph Health Care, London, ON, Canada, 5Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 6Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 7Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 10Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 11Rheumatology, Johns Hopkins University, Baltimore, MD, 12Divison of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasing in use in clinical practice. However, the absolute minimally important difference (MID) in…
  • « Previous Page
  • 1
  • …
  • 2058
  • 2059
  • 2060
  • 2061
  • 2062
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology